vs
Side-by-side financial comparison of ClearPoint Neuro, Inc. (CLPT) and Solana Co (HSDT). Click either name above to swap in a different company.
ClearPoint Neuro, Inc. is the larger business by last-quarter revenue ($10.4M vs $5.2M, roughly 2.0× Solana Co). On growth, Solana Co posted the faster year-over-year revenue change (2725.9% vs 34.0%). Over the past eight quarters, Solana Co's revenue compounded faster (522.3% CAGR vs 16.7%).
ClearPoint Neuro, Inc. is a medical technology firm specializing in precision neurology solutions. It develops and commercializes intraoperative navigation, targeting and delivery systems for minimally invasive brain surgeries, neurological disorder treatments, and CNS therapy development for global clinical and biopharmaceutical partners.
Solana is a Mexican cottage manufacturer of sports, racing, and kids' automobiles based in Mexico City. The family run company has operated since 1936, with a total production of fewer than fifty cars; the majority of them one-offs. The family is heavily involved in motor sports; the most prominent member was Moisés Solana, who raced family-built cars and later in Formula One.
CLPT vs HSDT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.4M | $5.2M |
| Net Profit | — | $325.6M |
| Gross Margin | 61.5% | 96.6% |
| Operating Margin | -67.7% | -3845.8% |
| Net Margin | — | 6227.1% |
| Revenue YoY | 34.0% | 2725.9% |
| Net Profit YoY | — | 8388.0% |
| EPS (diluted) | $-0.26 | $111.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.4M | $5.2M | ||
| Q3 25 | $8.9M | $697.0K | ||
| Q2 25 | $9.2M | $43.0K | ||
| Q1 25 | $8.5M | $49.0K | ||
| Q4 24 | $7.8M | $185.0K | ||
| Q3 24 | $8.1M | $51.0K | ||
| Q2 24 | $7.9M | $182.0K | ||
| Q1 24 | $7.6M | $135.0K |
| Q4 25 | — | $325.6M | ||
| Q3 25 | $-5.9M | $-352.8M | ||
| Q2 25 | $-5.8M | $-9.8M | ||
| Q1 25 | $-6.0M | $-3.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-5.0M | $-3.7M | ||
| Q2 24 | $-4.4M | $-1.6M | ||
| Q1 24 | $-4.1M | $-2.5M |
| Q4 25 | 61.5% | 96.6% | ||
| Q3 25 | 63.2% | 85.2% | ||
| Q2 25 | 60.3% | — | ||
| Q1 25 | 60.5% | — | ||
| Q4 24 | 61.3% | 16.8% | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 63.5% | 35.2% | ||
| Q1 24 | 59.2% | 8.9% |
| Q4 25 | -67.7% | -3845.8% | ||
| Q3 25 | -59.5% | -5086.1% | ||
| Q2 25 | -61.6% | -7725.6% | ||
| Q1 25 | -72.6% | -8185.7% | ||
| Q4 24 | -72.5% | — | ||
| Q3 24 | -63.5% | -7980.4% | ||
| Q2 24 | -60.1% | -1796.7% | ||
| Q1 24 | -55.2% | -2530.4% |
| Q4 25 | — | 6227.1% | ||
| Q3 25 | -66.5% | -50612.3% | ||
| Q2 25 | -63.3% | -22867.4% | ||
| Q1 25 | -71.0% | -7832.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -61.2% | -7227.5% | ||
| Q2 24 | -56.1% | -885.7% | ||
| Q1 24 | -54.3% | -1863.7% |
| Q4 25 | $-0.26 | $111.28 | ||
| Q3 25 | $-0.21 | $-32.89 | ||
| Q2 25 | $-0.21 | $-79.73 | ||
| Q1 25 | $-0.22 | $-0.51 | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.18 | $-744.35 | ||
| Q2 24 | $-0.16 | $-485.30 | ||
| Q1 24 | $-0.16 | $-3.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.9M | $7.3M |
| Total DebtLower is stronger | $49.1M | — |
| Stockholders' EquityBook value | $28.0M | $300.9M |
| Total Assets | $97.7M | $303.9M |
| Debt / EquityLower = less leverage | 1.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.9M | $7.3M | ||
| Q3 25 | $38.2M | $124.1M | ||
| Q2 25 | $41.5M | $6.1M | ||
| Q1 25 | $12.4M | $1.1M | ||
| Q4 24 | $20.1M | $1.1M | ||
| Q3 24 | $21.6M | $3.5M | ||
| Q2 24 | $32.8M | $6.4M | ||
| Q1 24 | $35.4M | $3.6M |
| Q4 25 | $49.1M | — | ||
| Q3 25 | $29.2M | — | ||
| Q2 25 | $28.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
| Q4 25 | $28.0M | $300.9M | ||
| Q3 25 | $15.9M | $-152.4M | ||
| Q2 25 | $19.7M | $6.0M | ||
| Q1 25 | $20.0M | $1.3M | ||
| Q4 24 | $25.4M | $1.1M | ||
| Q3 24 | $29.0M | $3.8M | ||
| Q2 24 | $32.1M | $6.3M | ||
| Q1 24 | $34.6M | $2.0M |
| Q4 25 | $97.7M | $303.9M | ||
| Q3 25 | $60.4M | $475.9M | ||
| Q2 25 | $62.9M | $7.9M | ||
| Q1 25 | $30.1M | $3.5M | ||
| Q4 24 | $39.2M | $3.5M | ||
| Q3 24 | $40.2M | $5.6M | ||
| Q2 24 | $52.6M | $8.8M | ||
| Q1 24 | $53.6M | $5.8M |
| Q4 25 | 1.75× | — | ||
| Q3 25 | 1.84× | — | ||
| Q2 25 | 1.46× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $-16.5M |
| Free Cash FlowOCF − Capex | $-12.1M | — |
| FCF MarginFCF / Revenue | -116.5% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | -0.05× |
| TTM Free Cash FlowTrailing 4 quarters | $-24.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | $-16.5M | ||
| Q3 25 | $-3.1M | $-4.0M | ||
| Q2 25 | $-2.6M | $-2.8M | ||
| Q1 25 | $-6.2M | $-3.5M | ||
| Q4 24 | $-1.2M | $-11.0M | ||
| Q3 24 | $-1.2M | $-2.8M | ||
| Q2 24 | $-2.7M | $-2.9M | ||
| Q1 24 | $-3.8M | $-3.0M |
| Q4 25 | $-12.1M | — | ||
| Q3 25 | $-3.3M | — | ||
| Q2 25 | $-2.6M | — | ||
| Q1 25 | $-6.4M | — | ||
| Q4 24 | $-1.5M | $-11.0M | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-3.0M |
| Q4 25 | -116.5% | — | ||
| Q3 25 | -37.5% | — | ||
| Q2 25 | -28.7% | — | ||
| Q1 25 | -74.9% | — | ||
| Q4 24 | -19.4% | -5970.8% | ||
| Q3 24 | -14.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -2226.7% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 3.4% | 2.7% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.0% | 3.7% |
| Q4 25 | — | -0.05× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLPT
| Neurosurgery Navigation And Therapy Disposable Products | $4.7M | 45% |
| Biologics And Drug Delivery Services And License Fees | $2.8M | 27% |
| Biologics And Drug Delivery Disposable Products | $2.4M | 23% |
| Other | $502.0K | 5% |
HSDT
Segment breakdown not available.
